Hyku Biosciences, Inc.
19.9.2023 13:32:27 CEST | ACCESS Newswire | Press release
- An innovative covalent platform for precision targeting of disease-causing proteins
- Seed financing led by RA Capital Management, Droia Ventures, and Novartis Venture Fund with participation from The Mark Foundation for Cancer Research, KB Investment and Eisai Innovation
LEXINGTON, MA / ACCESSWIRE / September 19, 2023 / Hyku Biosciences, Inc. (Hyku) today announced its launch with $56 million in seed financing to develop precision covalent medicines in oncology. Hyku is deploying an innovative chemoproteomics platform that selectively disarms disease-causing proteins by covalently targeting ligandable amino acids such as histidines, tyrosines or lysines. Hyku was incubated by RAVen, RA Capital Management's company creation engine, and is based on groundbreaking chemoproteomics research at the University of Virginia by its scientific founder, Dr. Ku-Lung (Ken) Hsu. Dr. Hsu is a recipient of The Mark Foundation's Emerging Leader Award and currently The Stephen F. and Fay Evans Martin Endowed Associate Professor of Chemistry at The University of Texas at Austin.
"Hyku was created with a singular focus to improve patient lives using the power of covalent medicines. Hyku's innovative and unique platform integrates chemoproteomics, proprietary chemistry and bespoke computational and machine-learning algorithms to target critically important amino acids such as histidines, tyrosines and lysines to expand the druggable proteome. We are proud to have a team of accomplished scientists led by our CSO, Mark Mulvihill, PhD, to achieve Hyku's vision." said Milind Deshpande, Ph.D., Founder, Acting CEO of Hyku and Venture Partner at RA Capital Management.
"Recent progress in covalent medicine has focused largely on targeting cysteines - Hyku builds on that progress, but now targeting proteins and sites only accessible with non-cysteine covalent chemistry," said Laura Tadvalkar, Ph.D., Managing Director at RA Capital Management and Hyku Board member. "We are proud to see the progress Hyku has made since its inception."
"We believe that precision covalent medicines provide a promising approach to address current and emerging challenges in oncology. Hyku's in-house chemoproteomics platform allows the team to make rapid progress across a range of pipeline programs - both internal and potentially with partners in the future. We look forward to working with the Hyku team and support their bold vision," said Matthias Van Woensel, Ph.D., Partner at Droia Ventures and Hyku Board member.
About Hyku Biosciences
Hyku Biosciences is a biotechnology company, based in the greater Boston area, building the leading covalent medicines discovery platform to inhibit disease targets which are challenging to address with conventional approaches. Hyku's drug discovery engine is based on its proprietary platform technologies, which identifies histidine, tyrosine and lysine based binding pockets and enables rational drug design for therapeutic development. The platform pioneered by Hyku has the potential to fundamentally expand the scope of small molecule drug discovery, greatly increase druggability across many target classes, and bring significant therapeutic benefits to patients via novel medicines. For more information, visit http://www.hykubiosciences.com
Contact:
SOURCE: Hyku Biosciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/784633/hyku-biosciences-launches-with-56m-to-advance-its-covalent-medicines-platform-to-expand-the-boundaries-of-drug-discovery
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AI Trading Changing Stock, Gold, and Forex Trading Market: Funds Coin's Multi-Agent Trading Update Dominates20.5.2026 11:00:00 CEST | Press release
DENVER, CO / ACCESS Newswire / May 20, 2026 / Ten years ago, algorithmic trading was the exclusive territory of investment banks and hedge funds. Today, a retail trader with $100 and a smartphone can access the same class of automated execution that once required a team of quants and millions in infrastructure. That's not an exaggeration. It's the shift that's quietly reshaping stock and forex markets, and AI trading agents are at the center of it. The Old Way Is Breaking Down Manual trading made sense when markets moved slowly enough for humans to keep up. That world no longer exists. Forex markets process over $7 trillion in daily volume. Crypto trades around the clock across hundreds of exchanges. Stock prices react to news in milliseconds. The information moves faster than any individual trader can process, and emotions, such as fear, greed, and hesitation, make an already difficult job even harder. The traders who thrived in this environment were either exceptionally disciplined o
Karbon-X and Evertrak Sign Letter of Intent to Advance Infrastructure-Linked Plastic Waste Reduction Credit Initiative19.5.2026 19:45:00 CEST | Press release
Proposed initiative would evaluate the potential generation of Verra-aligned Plastic Waste Reduction Credits for approximately 200,000 railroad ties made from recycled plastic currently installed across railroad infrastructure in North America. CALGARY, AB / ACCESS Newswire / May 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across compliance and voluntary environmental markets, today announced the signing of a Letter of Intent with Evertrak LLC ("Evertrak"), the leading manufacturer of Glass Fiber Reinforced Composite (GFRC) railroad ties made from recycled plastic, to explore an infrastructure-linked Plastic Waste Reduction Credit ("PWRC") initiative under Verra's Plastic Waste Reduction (PWR) Standard. Across North America, 20 million railroad ties made from wood are replaced annually. Approximately 4-6 million of those ties are less than 12 years old. Safe, resilient, and efficient railroad infrastr
AP Technologies Acquires Blueacre Technology, Adding Nitinol and Precision Laser Processing to Its Catheter Platform19.5.2026 16:00:00 CEST | Press release
Acquisition extends AP Technologies' vertically integrated catheter platform into nitinol and precision laser processing. Dundalk, Ireland joins the company's network of Centers of Excellence as its first European operation. SINGAPORE AND DUNDALK, IRELAND / ACCESS Newswire / May 19, 2026 / AP Technologies, a vertically integrated contract manufacturer of catheters and medical tubing, today announced the acquisition of Blueacre Technology, a Dundalk, Ireland specialist in laser micromachining and nitinol processing for the medical device industry. The acquisition establishes AP Technologies' first European operation in Ireland's medtech corridor, and extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices. Terms were not disclosed. Blueacre brings nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry, including femtosecond and picosecond laser cutting, laser we
Business Leaders Still Primarily Use AI for Simple Tasks, Study from General Assembly and EZRA Finds19.5.2026 15:00:00 CEST | Press release
Those who have received leadership-specific AI training more likely to use AI more often and more strategically NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / A new survey of more than 500 U.S. and U.K. business leaders found that while they are increasingly confident in their own AI skills, the most common use cases of the technology at the leadership level remain simple tasks like searching for information (69%), summarizing documents (68%) and drafting emails (58%). Strategic applications such as scenario planning (27%), organizational design (27%) and financial modeling (28%) lag far behind. The research was conducted by General Assembly, a global leader in practical AI skills training, in collaboration with EZRA, a leading global coaching and learning provider, both LHH brands. The study also surfaces a sharp divide between leadership levels. Vice presidents consistently fall behind director-level colleagues across nearly every measure of AI adoption and competence, emerging
Europe's Hospital Cybersecurity Hot Zones and Top Cyber Vendors as EHR and EPR Attacks Shift From Data Theft to Care Disruption19.5.2026 14:50:00 CEST | Press release
Recent European hospital incidents, NIS2 accountability, EPR exposure, supplier concentration, and 72-hour downtime weakness are pushing buyers toward clinical-continuity cybersecurity ahead of HIMSS26 Europe COPENHAGEN, DK / ACCESS Newswire / May 19, 2026 / Black Book Research today issued a new European hospital cybersecurity advisory identifying the countries, attack surfaces, vendor categories, and evaluation standards now shaping hospital cybersecurity buying decisions across Europe. The advisory builds on Black Book's Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey of 284 self-identified European hospital, health system, HIT, clinical-digital, cybersecurity, procurement, risk, and executive respondents seeking cybersecurity options around HIMSS26 Europe in Copenhagen. Black Book reports that European hospital cybersecurity has moved beyond breach response. The 2026 priority is now clinical availability: protecting EHRs, EPRs, identity systems, lab platforms, pharm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom